Home LiteratureArticle Details
PMID: 17341306 Published · epublish English

Time to decide about risk-reducing mastectomy: a case series of BRCA1/2 gene mutation carriers.

BMC women's health ·Vol. 7 ·2007-07-23

McCullum Mary, Bottorff Joan L, Kelly Mary, Kieffer Stephanie A, Balneaves Lynda G

Abstract

The purpose of this research was to explore women's decision-making experiences related to the option of risk-reducing mastectomy (RM), using a case series of three women who are carriers of a BRCA1/2 gene mutation.,Data was collected in a pilot study that assessed the response of women to an information booklet about RM and decision-making support strategies. A detailed analysis of three women's descriptions of their decision-making processes and outcomes was conducted.,All three women were carriers of a BRCA1/2 gene mutation and, although undecided, were leaning towards RM when initially assessed. Each woman reported a different RM decision outcome at last follow-up. Case #1 decided not to have RM, stating that RM was "too radical" and early detection methods were an effective strategy for dealing with breast cancer risk. Case #2 remained undecided about RM and, over time, she became less prepared to make a decision because she felt she did not have sufficient information about surgical effects. Case #3 had undergone RM by the time of her second follow-up interview and reported that she felt "a load off (her) mind now".,RM decision making may shift over time and require decision support over an extended period.

Article Info
Journal
BMC women's health
Abbr.
BMC Womens Health
Published
2007-07-23
Indexed
2007-03-22
Updated
2009-11-18
Language
English
Country/Region
England
NLM ID
101088690
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com